Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. 2006

Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
Centre for Military and Veterans Health, Mayne Medical School, Herston, Queensland 4006, Australia. s.kitchener@uq.edu.au

We conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers. After one injection, all subjects reported systemic reactions consistent with a mild dengue-like syndrome. Seven volunteers developed dengue 3 viraemia after vaccination. All subjects developed a neutralizing antibody response against serotype 3 with partial response against other serotypes. The trial was stopped early (after 10 subjects enrolled) due to formulation issues, which were related to the dengue 3 vaccine component. Managing viral interference and balancing attenuation to produce acceptable tetravalent immunogenicity with minimal reactogenicity may be a recurring problem for future multivalent live vaccines.

UI MeSH Term Description Entries
D008297 Male Males
D008889 Military Personnel Persons including soldiers involved with the armed forces. Air Force Personnel,Armed Forces Personnel,Army Personnel,Coast Guard,Marines,Navy Personnel,Sailors,Soldiers,Submariners,Military,Force Personnel, Air,Personnel, Air Force,Personnel, Armed Forces,Personnel, Army,Personnel, Military,Personnel, Navy,Sailor,Soldier,Submariner
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D003715 Dengue An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue. Dengue Fever,Break-Bone Fever,Breakbone Fever,Classical Dengue,Classical Dengue Fever,Break Bone Fever,Classical Dengue Fevers,Classical Dengues,Dengue Fever, Classical,Dengue, Classical,Fever, Break-Bone,Fever, Breakbone,Fever, Dengue
D003716 Dengue Virus A species of the genus FLAVIVIRUS which causes an acute febrile and sometimes hemorrhagic disease in man. Dengue is mosquito-borne and four serotypes are known. Breakbone Fever Virus,Breakbone Fever Viruses,Dengue Viruses,Fever Virus, Breakbone,Fever Viruses, Breakbone,Virus, Breakbone Fever,Virus, Dengue,Viruses, Breakbone Fever,Viruses, Dengue
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D001315 Australia The smallest continent and an independent country, comprising six states and two territories. Its capital is Canberra. Canton and Enderbury Islands,Christmas Island,Christmas Island (Australia)
D014613 Vaccines, Attenuated Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity. Attenuated Vaccine,Vaccines, Live, Attenuated,Attenuated Vaccines,Vaccine, Attenuated

Related Publications

Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
October 2013, Vaccine,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
March 2008, The American journal of tropical medicine and hygiene,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
August 2011, The American journal of tropical medicine and hygiene,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
May 2000, Vaccine,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
February 2024, The New England journal of medicine,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
November 2015, Vaccine,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
August 2020, The American journal of tropical medicine and hygiene,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
December 2003, The American journal of tropical medicine and hygiene,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
January 2011, The Pediatric infectious disease journal,
Scott Kitchener, and Michael Nissen, and Peter Nasveld, and Remi Forrat, and Sutee Yoksan, and Jean Lang, and Jean-François Saluzzo
January 2009, Human vaccines,
Copied contents to your clipboard!